SHP2 (Src Homology 2 Domain-Containing Phosphatase 2) is a widely expressed protein tyrosine phosphatase encoded by the PTPN11 gene. Originally identified as a positive regulator of RAS-RAF-MEK-ERK signaling downstream of growth factor receptors, SHP2 has emerged as a critical regulator of neuronal function, synaptic plasticity, and cell survival in the nervous system. Germline gain-of-function mutations in PTPN11 cause Noonan syndrome, a developmental disorder, while somatic mutations drive oncogenesis in various cancers. In the context of neurodegeneration, SHP2 plays complex and context-dependent roles—it's been implicated in both protective and pathogenic signaling in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurological conditions. The protein's enzymatic activity, adaptor functions, and subcellular localization are tightly regulated, with dysregulation contributing to neuronal dysfunction and death.
The PTPN11 gene (located on chromosome 12q24.13 in humans) encodes a protein of 593 amino acids with a molecular weight of approximately 68 kDa. SHP2 belongs to the protein tyrosine phosphatase (PTP) family and is one of two SH2 domain-containing phosphatases in mammals (the other being SHP1/PTPN6). Unlike SHP1, which is primarily expressed in hematopoietic cells, SHP2 is ubiquitously expressed with particularly high levels in the brain.
SHP2 possesses a characteristic multi-domain architecture:
N-terminal SH2 domain (NSH2): Binds to phosphotyrosine motifs on activated receptors and adaptor proteins. In the basal state, this domain interacts with the phosphatase domain to maintain autoinhibition.
C-terminal SH2 domain (CSH2): Provides additional protein-protein interaction surfaces and contributes to substrate specificity.
Protein tyrosine phosphatase (PTP) domain: The catalytic domain that removes phosphate groups from tyrosine residues on substrate proteins. Contains the signature HCX5R motif essential for catalysis.
C-terminal tail: Contains regulatory tyrosine phosphorylation sites and a proline-rich region for protein interactions.
The crystal structure reveals that in the inactive conformation, the NSH2 domain blocks access to the catalytic site. Activation requires binding to phosphotyrosine-containing peptides, which induces a conformational change that opens the active site. [1]
SHP2 is ubiquitously expressed with high levels in:
This broad expression reflects SHP2's fundamental role in cell signaling pathways that are conserved across tissue types. [2]
SHP2 is a well-established positive regulator of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) pathway:
Mechanism:
This function makes SHP2 essential for normal development and tissue homeostasis. [3]
In neurons, SHP2 plays critical roles in synaptic function:
Postsynaptic signaling:
Presynaptic function:
Learning and memory:
These findings demonstrate SHP2's essential role in cognitive function. [4][5]
SHP2 regulates both pro-survival and pro-death signaling:
Pro-survival functions:
Context-dependent roles:
Germline gain-of-function mutations in PTPN11 cause Noonan syndrome:
Clinical features:
Mechanism:
This established the critical role of SHP2 in development. [6]
Somatic PTPN11 mutations are found in various cancers:
Multiple SHP2 inhibitors are in clinical development for cancer therapy. [7]
SHP2 has complex roles in AD pathogenesis:
Pathological changes:
Mechanistic studies:
Therapeutic potential:
See: SHP2 and tau pathology [8]
In PD, SHP2 shows both protective and pathogenic roles:
Neuroprotection:
Pathogenic roles:
Therapeutic implications:
PTPN11 variants have been associated with ASD:
Genetic evidence:
Mechanism:
This links SHP2 to neurodevelopmental disorders. [10]
SHP2 interacts with numerous signaling proteins:
Receptors:
Adaptor proteins:
Enzymes:
SHP2 interacts with multiple signaling cascades:
PI3K-AKT pathway:
JAK-STAT pathway:
mTOR pathway:
Allosteric SHP2 inhibitors are in clinical development:
TNO155: First-in-class allosteric SHP2 inhibitor
RMC-4630: Another allosteric inhibitor
These compounds may also have utility in neurodegeneration. [11]
SHP2 modulators may be useful in:
In PD:
See: LRRK2
In AD:
See: Tau protein
See: PTEN
'Eck MJ, et al'. Structure of the SHP2 phosphatase domain. Cell. 2000. ↩︎
'Gauthier AS, et al'. SHP2 expression in the brain. Brain Res. 2007. ↩︎
'Liu X, et al'. SHP2 in RAS-RAF-MEK-ERK signaling. Nat Rev Cancer. 2016. ↩︎
'Baert L, et al'. SHP2 in neuronal function and synaptic plasticity. J Neurosci. 2017. ↩︎
'Yang Y, et al'. SHP2 regulates learning and memory. Learn Mem. 2015. ↩︎
'Tartaglia M, et al'. SHP2 mutations in Noonan syndrome. Nat Rev Genet. 2002. ↩︎
'Fortney K, et al'. SHP2 inhibitors for cancer therapy. Trends Cancer. 2021. ↩︎
'Kang H, et al'. SHP2 and Alzheimer's disease pathology. J Alzheimers Dis. 2020. ↩︎
'Zhu G, et al'. SHP2 in Parkinson's disease models. Nat Neurosci. 2019. ↩︎
'Turner TN, et al'. PTPN11 variants in autism spectrum disorder. Nat Neurosci. 2016. ↩︎
'Kwong E, et al'. Allosteric SHP2 inhibitors in clinical trials. J Med Chem. 2020. ↩︎